Sinqi Pharmaceutical (300573.SZ): SQ-25042 intraocular injection solution approved for clinical trials

Zhitongcaijing · 2d ago

Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration regarding the SQ-25042 intraocular injection solution. SQ-25042 intraocular injection solution is a fusion protein independently developed by the company. It is a class 1 innovative drug for therapeutic biological products. It is clinically intended to treat neovascularization (wet) age-related macular degeneration (NaMD), diabetic macular edema (DME), and macular oedema secondary to retinal vein occlusion (RVO).